局部剂量递增放疗可能改善胶质母细胞瘤患者的颅内局部控制与总生存
该回顾性分析纳入2009至2016年治疗的156例胶质母细胞瘤患者,比较标准60 Gy放疗与同步整合推量至66 Gy的剂量递增放疗。66 Gy组较60 Gy组颅内复发中位时间延长(12.2 vs 7.6个月,p=0.011),总生存改善(18.8 vs 15.3个月,p=0.012),多因素分析显示66 Gy放疗与颅内复发时间延长(HR=0.498,p=0.01)及总生存改善(HR=0.451,p=0.01)相关。
要点
- 66 Gy组较60 Gy组颅内复发中位时间延长(12.2 vs 7.6个月,p=0.011)。
- 66 Gy组较60 Gy组总生存改善(18.8 vs 15.3个月,p=0.012)。
- 多因素分析显示66 Gy放疗与颅内复发时间延长(HR=0.498,p=0.01)及总生存改善(HR=0.451,p=0.01)相关。
核心结论
- 在该胶质母细胞瘤队列中,放疗剂量递增与颅内复发时间延长及总生存改善相关。
- 作者认为这些结果需要进一步的前瞻性验证。
研究设计与样本
- 回顾性分析纳入2009至2016年治疗的156例胶质母细胞瘤患者,所有患者均适合术后放化疗。
- 剂量递增队列在小范围高危体积内接受同步整合推量至66 Gy(66 Gy放疗),其余患者接受每日放疗总剂量60 Gy或每日两次放疗总剂量59.2 Gy(60 Gy放疗)。
主要发现
- 133例患者接受标准60 Gy放疗,23例接受66 Gy放疗。
- 66 Gy放疗组患者更年轻(p < 0.001),而60 Gy放疗组同期替莫唑胺使用更频繁(p < 0.001)。
- 66 Gy放疗组较60 Gy放疗组颅内复发中位时间显著延长(12.2 vs 7.6个月,p = 0.011),总生存改善(18.8 vs 15.3个月,p = 0.012)。
- 多因素分析显示66 Gy放疗与颅内复发时间延长(风险比 = 0.498,p = 0.01)及总生存改善(风险比 = 0.451,p = 0.01)强相关。
- 采用基于分子标志物的预后评分后差异仍显著(颅内复发 p = 0.008,总生存 p = 0.007),倾向性评分匹配配对后颅内复发 p = 0.099、总生存 p = 0.023。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出这些结果需要进一步的前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The dismal overall survival (OS) prognosis of glioblastoma, even after trimodal therapy, can be attributed mainly to the frequent incidence of intracranial relapse (ICR), which tends to present as an in-field recurrence after a radiation dose of 60 Gray (Gy). In this study, molecular marker-based prognostic indices were used to compare the outcomes of radiation with a standard dose versus a moderate dose escalation. METHODS: This retrospective analysis included 156 patients treated between 2009 and 2016. All patients were medically fit for postoperative chemoradiotherapy. In the dose-escalation cohort a simultaneous integrated boost of up to 66 Gy (66 Gy RT) within small high-risk volumes was applied. All other patients received daily radiation to a total dose of 60 Gy or twice daily to a total dose of 59.2 Gy (60 Gy RT). RESULTS: A total of 133 patients received standard 60 Gy RT, while 23 received 66 Gy RT. Patients in the 66 Gy RT group were younger (p < 0.001), whereas concomitant temozolomide use was more frequent in the 60 Gy RT group (p < 0.001). Other intergroup differences in known prognostic factors were not observed. Notably, the median time to ICR was significantly prolonged in the 66 Gy RT arm versus the 60 Gy RT arm (12.2 versus 7.6 months, p = 0.011), and this translated to an improved OS (18.8 versus 15.3 months, p = 0.012). A multivariate analysis revealed a strong association of 66 Gy RT with a prolonged time to ICR (hazard ratio = 0.498, p = 0.01) and OS (hazard ratio = 0.451, p = 0.01). These differences remained significant after implementing molecular marker-based prognostic scores (ICR p = 0.008, OS p = 0.007) and propensity-scored matched pairing (ICR p = 0.099, OS p = 0.023). CONCLUSION: Radiation dose escalation was found to correlate with an improved time to ICR and OS in this cohort of glioblastoma patients. However, further prospective validation of these results is warranted.
引用
- Zschaeck S, Wust P, Graf R, et al. Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma. Radiat Oncol. 2018. PMID: 30567592. doi:10.1186/s13014-018-1194-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。